Latest News and Press Releases
Want to stay updated on the latest news?
-
60 Degrees Pharmaceuticals closes a $4M private placement for working capital and R&D, with stock and warrants priced at $1.38 per share.
-
60 Degrees Pharmaceuticals raises $4M through private placement for working capital, commercialization, and R&D, with H.C. Wainwright as placement agent.
-
60 Degrees Pharmaceuticals regains Nasdaq compliance after achieving a minimum closing bid price of $1.00 for 10 consecutive days.
-
60 Degrees Pharma Q2 2024 net product revenues doubled YoY to $125K, with an 18.3% sequential growth. Gross profit rose to $35K from a $124K loss.
-
60 Degrees Pharma grants U of Kentucky a right of reference to ARAKODA® NDA for a Phase IIb trial combining SJ733 with tafenoquine to treat vivax malaria.
-
60 Degrees Pharma (NASDAQ: SXTP) announces a 1-for-12 reverse stock split, effective August 12, 2024 to meet Nasdaq’s $1.00 minimum bid price requirement.
-
60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support
60 Degrees Pharmaceuticals secures a U.S. Army contract to support ARAKODA® packaging validation, with Q1 2024 sales up 515% year-over-year to $105.7K.
-
60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025
-
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.
-
60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.